RESUMEN

Methamphetamine (METH) is a highly addictive and widely abused drug worldwide. Although much research is on the drug's direct effects, METH may also alter host immunity. The mechanism by which METH influences immunity remains elusive. Here, C57BL6/J mice were intraperitoneally injected with 5 mg/kg METH four times at two-hour intervals. The microglial inhibitor minocycline or dopamine D1-like receptor antagonist SCH-23390 was also applied prior to METH injection. Twenty-four hours following the first METH injection, mice were challenged by lipopolysaccharide (LPS) at a dose of 330 µg/kg, and the hippocampus (Hip), caudate putamen (CPU), nucleus accumbens (NAc) and prefrontal cortex (PFC) were collected 4 h after LPS administration. IL-6 and TNF-α levels were detected by ELISA. The activation of D1-like receptors and microglial marker Iba1 were examined by immunohistochemical staining and Western blot. Finally, we examined the phosphorylation of ERK1/2 and CREB. We found that METH exposure increased LPS-induced IL-6 and TNF-α production in the Hip, CPU and NAc regions. METH also augmented microglia activation and D1/5DR expression in response to LPS. Moreover, administering SCH-23390 significantly reduced IL-6 and TNF-α production and Iba1 expression following LPS challenge. Similar inhibitory effects were also observed by minocycline administration. Moreover, phosphorylation of ERK1/2 and CREB was increased after METH and LPS exposure but decreased by SCH-23390. These data illustrate that METH exacerbates neuroinflammation response in LPS-stimulated mouse brains through dopamine D1-like receptors, microglia, and relevant signaling proteins, which may have therapeutic implications.

Asunto(s)

Encéfalo/efectos de los fármacos , Estimulantes del Sistema Nervioso Central/toxicidad , Inflamación/inmunología , Metanfetamina/toxicidad , Animales , Encéfalo/inmunología , Proteína de Unión a CREB/inmunología , Quinasas MAP Reguladas por Señal Extracelular/inmunología , Interleucina-6/inmunología , Lipopolisacáridos , Masculino , Ratones Endogámicos C57BL , Microglía/efectos de los fármacos , Microglía/inmunología , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D5/inmunología , Factor de Necrosis Tumoral alfa/inmunología

RESUMEN

Adolescence is a developmental period in which the mesolimbic dopaminergic "reward" circuitry of the brain, including the nucleus accumbens (NAc), undergoes significant plasticity. Dopamine D1 receptors (D1rs) in the NAc are critical for social behavior, but how these receptors are regulated during adolescence is not well understood. In this report, we demonstrate that microglia and complement-mediated phagocytic activity shapes NAc development by eliminating D1rs in male, but not female rats, during adolescence. Moreover, immune-mediated elimination of D1rs is required for natural developmental changes in male social play behavior. These data demonstrate for the first time that microglia and complement-mediated immune signaling (i) participate in adolescent brain development in a sex-specific manner, and (ii) are causally implicated in developmental changes in behavior. These data have broad implications for understanding the adolescent critical period of development, the molecular mechanisms underlying social behavior, and sex differences in brain structure and function.

Asunto(s)

Comunicación Animal , Microglía/fisiología , Núcleo Accumbens/crecimiento & desarrollo , Receptores de Dopamina D1/fisiología , Recompensa , Animales , Proteínas del Sistema Complemento/inmunología , Dopamina/metabolismo , Regulación hacia Abajo , Femenino , Masculino , Microglía/inmunología , Microglía/metabolismo , Modelos Animales , Núcleo Accumbens/inmunología , Núcleo Accumbens/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D1/antagonistas & inhibidores , Receptores de Dopamina D1/inmunología , Factores Sexuales

RESUMEN

There are many strategies to purify recombinant proteins of interest, and affinity purification utilizing monoclonal antibody that targets a linear epitope sequence is one of the essential techniques used in current biochemistry and structural biology. Here we introduce a new protein purification system using a very short CP5 tag. First, we selected anti-dopamine receptor D1 (DRD1) rabbit monoclonal antibody clone Ra62 (Ra62 antibody) as capture antibody, and identified its minimal epitope sequence as a 5-amino-acid sequence at C-terminal of DRD1 (GQHPT-COOH, D1CE sequence). We found that single amino acid substitution in D1CE sequence (GQHVT-COOH) increased dissociation rate up to 10-fold, and named the designed epitope sequence CP5 tag. Using Ra62 antibody and 2 peptides with different affinity, we developed a new affinity protein purification method, CP5 system. Ra62 antibody quickly captures CP5-tagged target protein, and captured CP5-tagged protein was eluted by competing with higher affinity D1CE peptide. By taking the difference of the affinity between D1CE and CP5, sharp elution under mild condition was achieved. Using CP5 system, we successfully purified deubiquitinase CYLD and E3 ubiquitin ligase MARCH3, and detected their catalytic activity. As to G protein-coupled receptors (GPCRs), 9 out of 12 cell-free synthesized ones were purified, demonstrating its purification capability of integral membrane proteins. CP5 tagged CHRM2 expressed by baculovirus-insect cell was also successfully purified by CP5 system. CP5 system offers several distinct advantages in addition to its specificity and elution performance. CP5 tag is easy to construct and handle because of its short length, which has less effect on protein characters. Mild elution of CP5 system is particulaly suitable for preparing delicate proteins such as enzymes and membrane proteins. Our data demonstrate that CP5 system provides a new promising option in protein sample preparation with high yield, purity and activity for downstream applications in functional and structural analysis.

Asunto(s)

Cromatografía de Afinidad/métodos , Proteínas Recombinantes/aislamiento & purificación , Sustitución de Aminoácidos , Animales , Anticuerpos Monoclonales/inmunología , Células CHO , Proteínas Portadoras/aislamiento & purificación , Proteínas Portadoras/metabolismo , Sistema Libre de Células , Cricetulus , Enzima Desubiquitinante CYLD , Epítopos/genética , Epítopos/inmunología , Células HEK293 , Células HeLa , Humanos , Immunoblotting , Células MCF-7 , Proteínas de la Membrana/aislamiento & purificación , Proteínas de la Membrana/metabolismo , Conejos , Receptores de Dopamina D1/genética , Receptores de Dopamina D1/inmunología , Lugares Marcados de Secuencia , Proteínas Supresoras de Tumor/aislamiento & purificación , Proteínas Supresoras de Tumor/metabolismo , Ubiquitina-Proteína Ligasas

RESUMEN

Dopamine receptors 1 and 2 (DRD1, DRD2) are essential for signaling in the brain for a multitude of brain functions. Previous work using several antibodies against these receptors is abundant but only the minority of antibodies used have been validated and, therefore, the results of these studies remain uncertain. Herein, antibodies against DRD1 (Merck Millipore AB1765P, Santa Cruz Biotechnology sc-14001, Sigma Aldrich D2944, Alomone Labs ADR-001) and DRD2 (Abcam ab21218, Merck Millipore AB5084P, Santa Cruz Biotechnology sc-5303) have been tested using western blotting and immunohistochemistry on mouse striatum (wild type and corresponding knock-out mice) and when specific, they were further evaluated on rat and human striatum. Moreover, a DRD1 antibody and a DRD2 antibody that were found specific in our tests were used for immunoprecipitation with subsequent mass spectrometrical identification of the immunoprecipitate. Two out of nine antibodies (anti DRD1 Sigma Aldrich D2944 and anti DRD2 Merck Millipore AB5084P) against the abovementioned dopamine receptors were specific for DRD1 and DRD2 as evaluated by western blotting and immunohistochemistry and the immunoprecipitate indeed contained DRD1 and DRD2 as revealed by mass spectrometry. The observed findings may question the use of so far non-validated antibodies against the abovementioned dopamine receptors. Own observations may be valuable for the interpretation of previous results and the design of future studies using dopamine receptors DRD1 or DRD2.

Asunto(s)

Anticuerpos , Especificidad de Anticuerpos , Cuerpo Estriado/inmunología , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/inmunología , Animales , Anticuerpos/inmunología , Anticuerpos/farmacología , Ratones , Ratones Noqueados , Receptores de Dopamina D1/genética , Receptores de Dopamina D2/genética

RESUMEN

Polypeptide tag technology is widely used for protein detection and affinity purification. It consists of two fundamental elements: a peptide sequence and a binder which specifically binds to the peptide tag. In many tag systems, antibodies have been used as binder due to their high affinity and specificity. Recently, we obtained clone Ra48, a high-affinity rabbit monoclonal antibody (mAb) against dopamine receptor D1 (DRD1). Here, we report a novel tag system composed of Ra48 antibody and its epitope sequence. Using a deletion assay, we identified EEAAGIARP in the C-terminal region of DRD1 as the minimal epitope of Ra48 mAb, and we named this sequence the "AGIA" tag, based on its central sequence. The tag sequence does not include the four amino acids, Ser, Thr, Tyr, or Lys, which are susceptible to post-translational modification. We demonstrated performance of this new tag system in biochemical and cell biology applications. SPR analysis demonstrated that the affinity of the Ra48 mAb to the AGIA tag was 4.90 × 10-9 M. AGIA tag showed remarkably high sensitivity and specificity in immunoblotting. A number of AGIA-fused proteins overexpressed in animal and plant cells were detected by anti-AGIA antibody in immunoblotting and immunostaining with low background, and were immunoprecipitated efficiently. Furthermore, a single amino acid substitution of the second Glu to Asp (AGIA/E2D) enabled competitive dissociation of AGIA/E2D-tagged protein by adding wild-type AGIA peptide. It enabled one-step purification of AGIA/E2D-tagged recombinant proteins by peptide competition under physiological conditions. The sensitivity and specificity of the AGIA system makes it suitable for use in multiple methods for protein analysis.

Asunto(s)

Anticuerpos Monoclonales/metabolismo , Cromatografía de Afinidad/métodos , Fragmentos de Péptidos/inmunología , Receptores de Dopamina D1/química , Receptores de Dopamina D1/metabolismo , Secuencia de Aminoácidos , Animales , Afinidad de Anticuerpos , Línea Celular Tumoral , Epítopos/inmunología , Células HEK293 , Células HeLa , Humanos , Células MCF-7 , Ratones , Células 3T3 NIH , Unión Proteica , Conejos , Receptores de Dopamina D1/análisis , Receptores de Dopamina D1/inmunología

RESUMEN

G-protein-coupled receptors (GPCRs) are one of the most important drug targets, and anti-GPCR monoclonal antibody (mAb) is an essential tool for functional analysis of GPCRs. However, it is very difficult to develop GPCR-specific mAbs due to difficulties in production of recombinant GPCR antigens, and lack of efficient mAb screening method. Here we describe a novel approach for the production of mAbs against GPCR using two original methods, bilayer-dialysis method and biotinylated liposome-based interaction assay (BiLIA), both of which are developed using wheat cell-free protein synthesis system and liposome technology. Using bilayer-dialysis method, various GPCRs were successfully synthesized with quality and quantity sufficient for immunization. For selection of specific mAb, we designed BiLIA that detects interaction between antibody and membrane protein on liposome. BiLIA prevented denaturation of GPCR, and then preferably selected conformation-sensitive antibodies. Using this approach, we successfully obtained mAbs against DRD1, GHSR, PTGER1 and T1R1. With respect to DRD1 mAb, 36 mouse mAbs and 6 rabbit mAbs were obtained which specifically recognized native DRD1 with high affinity. Among them, half of the mAbs were conformation-sensitive mAb, and two mAbs recognized extracellular loop 2 of DRD1. These results indicated that this approach is useful for GPCR mAb production.

Asunto(s)

Anticuerpos Monoclonales/inmunología , Receptores de Dopamina D1/inmunología , Receptores Acoplados a Proteínas G/inmunología , Receptores de Ghrelina/inmunología , Subtipo EP1 de Receptores de Prostaglandina E/inmunología , Animales , Anticuerpos Monoclonales/biosíntesis , Afinidad de Anticuerpos/inmunología , Biotinilación , Sistema Libre de Células , Células Cultivadas , Ensayo de Inmunoadsorción Enzimática , Mapeo Epitopo , Epítopos/inmunología , Humanos , Liposomas/inmunología , Ratones , Conejos , Proteínas Recombinantes/síntesis química , Proteínas Recombinantes/inmunología

RESUMEN

MDSCs accumulate in tumor-bearing animals and cancer patients and are a major factor responsible for cancer-induced immunosuppression that limits effective cancer immunotherapy. Strategies aimed at effectively inhibiting the function of MDSCs are expected to enhance host anti-tumor immunity and improve cancer immunotherapy significantly. The neurotransmitter DA has been found to have anti-cancer activity, but the underlying mechanism is poorly understood. In this study, we sought to investigate the therapeutic mechanism and efficacy of DA on the inhibition of cancer development via the regulation of MDSC functions. The regulation of the suppressive function of Gr-1(+)CD115(+) MDSCs by DA was determined by use of murine syngeneic LLC and B16 graft models treated with DA in vivo, as well as Gr-1(+)CD115(+) MDSCs isolated from these model treated with DA ex vivo. Here, we show that Gr-1(+)CD115(+) monocytic MDSCs express D1-like DA receptors. DA dramatically attenuated the inhibitory function of tumor-induced monocytic MDSCs on T cell proliferation and IFN-γ production via D1-like DA receptors and retarded tumor growth. DA and other D1 receptor agonists inhibited IFN-γ-induced NO production by MDSCs from tumor-bearing mice and cancer patients. Decreased NO production was, in part, mediated via the suppression of p-ERK and p-JNK. In conclusion, the neurotransmitter DA potently inhibits the suppressive function of MDSC and enhances anti-tumor immunity. Our finding provides a mechanistic basis for the use of DA or D1-like receptor agonists to overcome tumor-induced immunosuppression in cancer immunotherapy.

Asunto(s)

Dopamina/inmunología , Tolerancia Inmunológica/inmunología , Células Mieloides/inmunología , Neoplasias Experimentales/inmunología , Animales , Dopamina/farmacología , Citometría de Flujo , Humanos , Immunoblotting , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos C57BL , Células Mieloides/efectos de los fármacos , Receptores de Dopamina D1/inmunología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa

RESUMEN

Adverse experiences during gestation such as maternal stress and infection are known risk factors for neurodevelopmental disorders, including schizophrenia, autism, and attention deficit/hyperactivity disorder. The mechanisms by which these distinct exposures may confer similar psychiatric vulnerability remain unclear, although likely involve pathways common to both stress and immune responses at the maternal-fetal interface. We hypothesized that maternal stress-induced activation of immune pathways within the placenta, the sex-specific maternal-fetal intermediary, may contribute to prenatal stress programming effects on the offspring. Therefore, we assessed for markers indicative of stress-induced placental inflammation, and examined the ability of maternal nonsteroidal antiinflammatory drug (NSAID) treatment to ameliorate placental effects and thereby rescue the stress-dysregulation phenotype observed in our established mouse model of early prenatal stress (EPS). As expected, placental gene expression analyses revealed increased levels of immune response genes, including the proinflammatory cytokines IL-6 and IL-1ß, specifically in male placentas. NSAID treatment partially ameliorated these EPS effects. Similarly, in adult offspring, males displayed stress-induced locomotor hyperactivity, a hallmark of dopaminergic dysregulation, which was ameliorated by maternal NSAID treatment. Fitting with these outcomes and supportive of dopamine pathway involvement, expression of dopamine D1 and D2 receptors was altered by EPS in males. These studies support an important interaction between maternal stress and a proinflammatory state in the long-term programming effects of maternal stress.

Asunto(s)

Antiinflamatorios no Esteroideos/farmacología , Actividad Motora/efectos de los fármacos , Placenta/efectos de los fármacos , Efectos Tardíos de la Exposición Prenatal/inmunología , Estrés Psicológico/inmunología , Animales , Antiinflamatorios no Esteroideos/inmunología , Western Blotting , Encéfalo/efectos de los fármacos , Encéfalo/inmunología , Encéfalo/metabolismo , Femenino , Expresión Génica/efectos de los fármacos , Expresión Génica/inmunología , Humanos , Interleucina-1beta/genética , Interleucina-1beta/inmunología , Interleucina-6/genética , Interleucina-6/inmunología , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Actividad Motora/inmunología , Placenta/inmunología , Placenta/metabolismo , Embarazo , Efectos Tardíos de la Exposición Prenatal/psicología , Receptores de Dopamina D1/genética , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/genética , Receptores de Dopamina D2/inmunología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores Sexuales , Estrés Psicológico/psicología , Tirosina 3-Monooxigenasa/inmunología , Tirosina 3-Monooxigenasa/metabolismo

RESUMEN

BACKGROUND: Sydenham chorea (SC), a neuropsychiatric sequela of group-A streptococcal infection, is associated with basal ganglia autoantibodies. Although autoantibodies have been proposed in neuropsychiatric disorders, little evidence has been shown to link autoimmunity and clinical symptoms. We hypothesized that dopamine receptor-autoantibody interactions may be the basis of neuropsychiatric symptoms in SC. METHODS: Sera from 22 children with SC (age 10.7±4.5 years) and 22 age-matched controls were studied. Clinical neuropsychiatric symptoms were measured in SC at sample collection using the UFMG-Sydenham's-Chorea-Rating-Scale (USCRS). Anti-dopamine D1 receptor (D1R) and anti-dopamine D2 receptor (D2R) autoantibodies were measured by the enzyme linked immunosorbent assay (ELISA) and were correlated with clinical symptoms. RESULTS: Anti-D1R and anti-D2R autoantibodies were significantly higher in SC compared to controls (n = 44; p = 0.010 and p = 0.017, respectively). We found that the ratio (anti-D2R/D1R) of the two anti-dopaminergic receptor antibodies correlated with neuropsychiatric symptoms as determined by USCRS measurements (n = 18; r = 0.53, p = 0.024). In addition, anti-D2R titers correlated with antistreptolysin-O titers (n = 43; r = 0.49, p = 0.0008). INTERPRETATION: Our report linked, for the first time, autoimmunity with neuropsychiatric symptoms. The significant correlation was found using ratios of autoantibodies against dopamine receptors (anti-D2R/D1R) rather than the absolute elevated individual anti-D1R or anti-D2R titers. We suggest that autoantibodies may lead to a receptor imbalance and induce greater sensitivity to dopamine signaling potentially leading to neuropsychiatric symptoms in SC. Our novel findings suggesting altered balance in the dopaminergic system may provide a new approach in understanding autoimmune neuropsychiatric disorders with possible implications for diagnosis and treatment.

Asunto(s)

Autoanticuerpos/sangre , Corea/diagnóstico , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/inmunología , Infecciones Estreptocócicas/diagnóstico , Adolescente , Adulto , Estudios de Casos y Controles , Niño , Preescolar , Corea/inmunología , Corea/microbiología , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Pronóstico , Infecciones Estreptocócicas/inmunología , Infecciones Estreptocócicas/microbiología , Adulto Joven

RESUMEN

The study has shown that activation of delta1-opioid receptors by a highly selective peptide agonist DPDPE (100 microg/kg) results in a significant increase of the immune response to antigen (SRBC, 5 x 10(8)) in CBA mice. SCH-23390 (1 mg/kg), a selective antagonist of the postsynaptic dopamine D1-receptors, and selective D2-blocker haloperidol (1 mg/kg) prevented immunostimulating effect of DPDPE. Comparison of effects of the antagonists suggests that delta1-opioidergic immunostimulation has more significant impact due to involvement of dopamine D1-receptors.

Asunto(s)

Inmunización , Receptores de Dopamina D1 , Receptores de Dopamina D2 , Receptores Opioides delta/inmunología , Animales , Antagonistas de Dopamina/metabolismo , Antagonistas de Dopamina/farmacología , Antagonistas de los Receptores de Dopamina D2 , Encefalina D-Penicilamina (2,5)/metabolismo , Encefalina D-Penicilamina (2,5)/farmacología , Haloperidol/metabolismo , Haloperidol/farmacología , Antígenos de Histocompatibilidad Clase II/metabolismo , Inmunidad Activa/efectos de los fármacos , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Masculino , Ratones , Ratones Endogámicos CBA , Neurotransmisores/metabolismo , Neurotransmisores/farmacología , Receptores de Dopamina D1/antagonistas & inhibidores , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/inmunología

RESUMEN

It is established that preliminary blockade ofdopamine (DA) D2 receptors with haloperidol prevents immunostimulation observed upon the activation of D1 receptors with selective agonist SKF 38393 in mice of the CBA and C57BL/6J strains having no experience in social confrontations. These data are indicative of the functional interconnection between DA receptors of the D1 and D2 subtypes in the immune response control. Similar link between these DA receptor subtypes has been also found in C57BL/6J mice conditioned to display aggressive or submissive behaviors during 10-day social encounter testing. The data obtained give evidence that the interaction between D1 and D2 receptors is manifested in animals with various genotypes and psychoemotional states.

Asunto(s)

Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/inmunología , Estrés Psicológico/inmunología , 2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Agresión/efectos de los fármacos , Animales , Conducta Animal/efectos de los fármacos , Agonistas de Dopamina/farmacología , Ratones , Ratones Endogámicos CBA , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D2/agonistas , Especificidad de la Especie

RESUMEN

OBJECTIVE: Dopamine exists in the immune system and has obvious immunomodulating action. However, receptor mechanism underlying the dopamine immunomodulation remains to be clarified. In the present study, we provide the evidence for existence of dopamine receptor subtypes in T lymphocytes and show the roles of the receptors and the receptor-coupled signaling in mediating the dopamine immunomodulation. METHODS: The purified T lymphocytes from the mesenteric lymph nodes of mice were detected for expressions of all five subtypes of dopamine receptor mRNAs by reverse transcription-polymerase chain reaction. Lymphocyte proliferation and production of interferon-γ (IFN-γ) and interleukin-4 (IL-4) in response to concanavalin A (Con A) were measured by colorimetric methyl-thiazole-tetrazolium assay and cytometric bead array, respectively, after the cells were exposed to dopamine D1-like or D2-like receptor agonists and antagonists. Meanwhile, content of cAMP and phosphorylation of cAMP-response element-binding (CREB) in the lymphocytes were examined by 125I-cAMP radioimmunoassay and Western blot assay, respectively. RESULTS: T lymphocytes expressed all the five subtypes of dopamine receptor mRNAs, i.e., D1, D2, D3, D4 and D5 receptors. SKF38393, an agonist of dopamine D1-like receptors (D1 and D5 receptors) only reduced the IFN-γ production, but did not significantly affect the proliferative response, IL-4 production, cAMP content or CREB activation of the lymphocytes. The SKF38393-induced decrease in IFN-γ level was blocked by the D1-like receptor antagonist SCH23390. Quinpirole, an agonist of dopamine D2-like receptors (D2, D3 and D4 receptors) attenuated the lymphocyte proliferation to Con A, and decreased the IFN-γ but increased the IL-4 production. Meanwhile, the quinpirole diminished the cAMP content and the phosphorylated CREB level in the lymphocytes. All the quinpirole-induced changes were reversed by dopamine D2-like receptor antagonist haloperidol. CONCLUSIONS: Five dopamine receptor subtypes of the two families, D1-like and D2-like receptors, exist on T lymphocytes of mice. Of the two families, D2-like receptors are more important in mediating modulation of T cell function than D1-like receptors. D2-like receptors are involved in suppression of T helper 1 (Th1) cell function and enhancement of Th2 cell function through negative link to cAMP-CREB pathway.

Asunto(s)

Proteína de Unión a CREB/metabolismo , Interferón gamma/metabolismo , Interleucina-4/metabolismo , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/inmunología , Transducción de Señal , Linfocitos T/inmunología , 2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Animales , Benzazepinas/farmacología , Western Blotting , Proliferación Celular/efectos de los fármacos , Agonistas de Dopamina/farmacología , Antagonistas de Dopamina/farmacología , Ratones , Fosforilación/efectos de los fármacos , ARN Mensajero/metabolismo , Radioinmunoensayo , Receptores Dopaminérgicos/clasificación , Receptores Dopaminérgicos/genética , Receptores Dopaminérgicos/inmunología , Receptores de Dopamina D3/inmunología , Receptores de Dopamina D4/inmunología , Receptores de Dopamina D5/inmunología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Linfocitos T/metabolismo

RESUMEN

A major neurotransmitter dopamine transmits signals via five different seven transmembrane G protein-coupled receptors termed D1-D5. It is now evident that dopamine is released from leukocytes and acts as autocrine or paracrine immune modulator. However, the role of dopamine for dendritic cells (DCs) and T(h) differentiation remains unclear. We herein demonstrate that human monocyte-derived dendritic cells (Mo-DCs) stored dopamine in the secretary vesicles. The storage of dopamine in Mo-DCs was enhanced by forskolin and dopamine D2-like receptor antagonists via increasing cyclic adenosine 3',5'-monophosphate (cAMP) formation. Antigen-specific interaction with naive CD4(+) T cells induced releasing dopamine-including vesicles from Mo-DCs. In naive CD4(+) T cells, dopamine dose dependently increased cAMP levels via D1-like receptors and shifts T-cell differentiation to T(h)2, in response to anti-CD3 plus anti-CD28 mAb. Furthermore, we demonstrated that dopamine D2-like receptor antagonists, such as sulpiride and nemonapride, induced a significant DC-mediated T(h)2 differentiation, using mixed lymphocyte reaction between human Mo-DCs and allogeneic naive CD4(+) T cells. When dopamine release from Mo-DCs is inhibited by colchicines (a microtubule depolymerizer), T-cell differentiation shifts toward T(h)1. These findings identify DCs as a new source of dopamine, which functions as a T(h)2-polarizing factor in DC-naive T-cell interface.

Asunto(s)

Diferenciación Celular/inmunología , Células Dendríticas/metabolismo , Dopamina/metabolismo , Células Th2/inmunología , Benzamidas/farmacología , Comunicación Celular/inmunología , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Colchicina/farmacología , Colforsina/farmacología , AMP Cíclico/metabolismo , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Dopamina/inmunología , Antagonistas de los Receptores de Dopamina D2 , Humanos , Activación de Linfocitos , Prueba de Cultivo Mixto de Linfocitos , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D1/metabolismo , Receptores de Dopamina D2/inmunología , Vesículas Secretoras/efectos de los fármacos , Vesículas Secretoras/inmunología , Sulpirida/farmacología , Células TH1/efectos de los fármacos , Células TH1/inmunología , Células Th2/efectos de los fármacos

RESUMEN

Evidence indicate that it is difficult to obtain specific antibodies to G protein-coupled receptors and different technical difficulties may allow the generation of antibodies that lack specificity. We conducted experiments to validate the specificity of commercially available antibodies raised against dopamine (DA) receptors hD(1), hD(4), and hD(5) using a transfection approach: we studied whether, in HEK 293 cells selectively transfected with the various cloned subtypes, each antibody generates bands only in cells expressing its cognate receptor but not in those expressing the other DA receptors. Our results demonstrated that hD(1) and hD(4) receptor antibodies recognize not only their respective epitope, but also other DA receptor subtypes, while for the hD(5) receptor detection, we observed a signal only in the lane loaded with hD(5)-transfected HEK 293 cells, although with a lack of purity. Therefore, we recommend caution on the use of commercially available DA receptor antibodies.

Asunto(s)

Anticuerpos/inmunología , Especificidad de Anticuerpos/inmunología , Receptores Dopaminérgicos/análisis , Receptores Dopaminérgicos/inmunología , Western Blotting , Línea Celular , Humanos , Receptores Dopaminérgicos/genética , Receptores de Dopamina D1/análisis , Receptores de Dopamina D1/genética , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/análisis , Receptores de Dopamina D2/genética , Receptores de Dopamina D2/inmunología , Receptores de Dopamina D3/análisis , Receptores de Dopamina D3/genética , Receptores de Dopamina D3/inmunología , Receptores de Dopamina D4/análisis , Receptores de Dopamina D4/genética , Receptores de Dopamina D4/inmunología , Receptores de Dopamina D5/análisis , Receptores de Dopamina D5/genética , Receptores de Dopamina D5/inmunología , Transfección

RESUMEN

The interaction between dopamine D1 and D2 receptors plays a role in immunomodulation. The results of thus interaction depends on the degree of receptor activation with selective agonists in different doses. Combined treatment with agonists of D1 and D2 receptors in high doses had a synergistic effect in the mechanisms of immunomodulation. Receptor agonists in low doses suppressed the immune response. Our results suggest that weak activation of one of these receptors is accompanied by inactivation of the other receptor type.

Asunto(s)

Dopaminérgicos/farmacología , Factores Inmunológicos/farmacología , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D1/metabolismo , Receptores de Dopamina D2/inmunología , Receptores de Dopamina D2/metabolismo , 2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Animales , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Masculino , Ratones , Ratones Endogámicos CBA , Quinpirol/farmacología , Bazo/inmunología , Bazo/patología

RESUMEN

The study has shown that activation of mu-opioid receptors by a highly selective agonist DAGO (100 microg/kg) results in a significant increase of the immune response to antigen (SRBC, 5% 10(8)) in CBA mice. Haloperidol (2 mg/kg), a selective antagonist of the postsynaptic dopamine (DA) receptors, prevented immunostimulating effect of DAGO. In contrast, selective D1--antagonist SCH 23390 (1 mg/kg) did not affect on DAGO-induced enhancing of immune reactivity. At the same time, the blockade of both types of DA receptors (D1 and D2) caused similar immunosuppressing effects. These data suggest a possible differential role for D1 and D2 receptors in mu-opioidergic immunomodulation.

Asunto(s)

Analgésicos Opioides/farmacología , Formación de Anticuerpos/efectos de los fármacos , Antagonistas de Dopamina/farmacología , Antagonistas de los Receptores de Dopamina D2 , Encefalina Ala(2)-MeFe(4)-Gli(5)/farmacología , Haloperidol/farmacología , Receptores de Dopamina D1/antagonistas & inhibidores , Receptores Opioides mu/agonistas , Animales , Formación de Anticuerpos/inmunología , Masculino , Ratones , Ratones Endogámicos CBA , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/inmunología , Receptores Opioides mu/inmunología

RESUMEN

Morphine suppresses a number of immune parameters, such as natural killer (NK) cell activity and lymphocyte proliferation, by acting through mu-opioid receptors in the central nervous system. Prior studies have implicated the sympathetic nervous system in mediating the immunomodulatory effects of acute morphine treatment. However, the peripheral mechanism whereby morphine inhibits NK cell activity is not fully understood. The aim of the present study was to investigate the role of the sympathetic transmitter neuropeptide Y (NPY) in mediating morphine-induced immune alterations. The results showed that administration of the selective NPY Y1 receptor antagonist BIBP3226 blocked morphine's effect on splenic NK activity but did not attenuate the suppression splenocyte proliferative responses to Con-A or LPS. Furthermore, intravenous NPY administration produced a dose-dependent inhibition of splenic NK activity but did not suppress lymphocyte proliferation. Recent studies from our laboratory have demonstrated that morphine modulates NK activity through a central mechanism that requires the activation of dopamine D1 receptors in the nucleus accumbens. Results from the present study showed that microinjection of the D1 receptor agonist SKF-38393 into the nucleus accumbens shell induced a suppression of NK activity that was reversed by BIBP3226. Collectively, these findings demonstrate that NPY Y1 receptors mediate morphine's suppressive effect on NK activity and further suggest that opioid-induced increases in nucleus accumbens D1 receptor activation inhibit splenic NK activity via NPY released from the sympathetic nervous system.

Asunto(s)

Tolerancia Inmunológica/efectos de los fármacos , Células Asesinas Naturales/efectos de los fármacos , Dependencia de Morfina/complicaciones , Dependencia de Morfina/inmunología , Morfina/farmacología , Receptores de Neuropéptido Y/efectos de los fármacos , 2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Animales , Ansiolíticos/farmacología , Arginina/análogos & derivados , Arginina/farmacología , Modelos Animales de Enfermedad , Agonistas de Dopamina/farmacología , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/inmunología , Interacciones Farmacológicas/fisiología , Tolerancia Inmunológica/inmunología , Células Asesinas Naturales/inmunología , Masculino , Dependencia de Morfina/fisiopatología , Narcóticos/farmacología , Neuroinmunomodulación/efectos de los fármacos , Neuroinmunomodulación/inmunología , Neuropéptido Y/inmunología , Neuropéptido Y/metabolismo , Neuropéptido Y/farmacología , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/inmunología , Núcleo Accumbens/metabolismo , Ratas , Ratas Endogámicas Lew , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D1/metabolismo , Receptores de Neuropéptido Y/inmunología , Receptores de Neuropéptido Y/metabolismo , Bazo/citología , Bazo/efectos de los fármacos , Bazo/inmunología , Sistema Nervioso Simpático/efectos de los fármacos , Sistema Nervioso Simpático/inmunología , Sistema Nervioso Simpático/fisiopatología

RESUMEN

Dopamine is an important modulator of blood pressure, in part, by regulating vascular resistance. To test the hypothesis that D(1) and D(3) receptors interact in vascular smooth muscle cells, we studied A10 cells, a rat aortic smooth muscle cell line, and rat mesenteric arteries that express both dopamine receptor subtypes. Fenoldopam, a D(1)-like receptor agonist, increased both D(1) and D(3) receptor protein in a time-dependent and a concentration-dependent manner in A10 cells. The effect of fenoldopam was specific because a D(1)-like receptor antagonist, SCH23390 (10(-7) M/24 h), completely blocked the stimulatory effect of fenoldopam (10(-7) M/24 h) (D(3) receptor: control=21+/-1 density units [DU]); SCH23390=23+/-2 DU; fenoldopam=33+/-2 DU; fenoldopam+SCH23390=23+/-2 DU; n=10). D(1) and D(3) receptors physically interacted with each other because fenoldopam (10(-7) M/24 h) increased D(1)/D(3) receptor coimmunoprecipitation (35+/-5 versus 65+/-5 DU; n=8). A D(3) receptor agonist, PD128907, relaxed mesenteric arterial rings independent of the endothelium, effects that were blocked by a D(3) receptor antagonist, U99194A. Costimulation of D(1) and D(3) receptors led to additive vasorelaxation. We conclude that the D(1) receptor regulates the D(3) receptor by physical interaction and receptor expression. D(1) receptor stimulation augments D(3) receptor vasorelaxant effects. An interaction of D(1) and D(3) receptors may be involved in the regulation of blood pressure.

Asunto(s)

Músculo Liso Vascular/fisiología , Receptores de Dopamina D1/metabolismo , Receptores de Dopamina D2/metabolismo , Animales , Especificidad de Anticuerpos , Aorta/citología , Línea Celular , Técnicas de Cultivo , Agonistas de Dopamina/farmacología , Antagonistas de Dopamina/farmacología , Fenoldopam/farmacología , Masculino , Arterias Mesentéricas/anatomía & histología , Arterias Mesentéricas/química , Arterias Mesentéricas/fisiología , Músculo Liso Vascular/citología , Músculo Liso Vascular/efectos de los fármacos , Ratas , Ratas Endogámicas WKY , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D2/agonistas , Receptores de Dopamina D2/inmunología , Receptores de Dopamina D3 , Vasodilatación/efectos de los fármacos

RESUMEN

The roles of the G-protein alpha-subunits, Gs, Gi, and Gq/11, in the signal transduction of the D1-like dopamine receptors, D1 and D5, have been deciphered. Galpha12 and Galpha13, members of the 4th family of G protein subunits, are not linked with D1 receptors, and their linkage to D5 receptors is not known. Therefore, we studied the expression of Galpha12 and Galpha13 and interaction with D5 dopamine receptors in the kidney from normotensive Wistar-Kyoto (WKY) rats and D5 receptor-transfected HEK293 cells. Galpha12 and Galpha13 were found in the proximal tubule, distal convoluted tubule, and artery and vein in the WKY rat kidney. Whereas Galpha12 was expressed in the ascending limb of Henle, Galpha13 was expressed in the collecting duct and juxtaglomerular cells. In renal proximal tubules, Galpha12 and Galpha13, as with D5 receptors, were expressed in brush border membranes. Laser confocal microscopy revealed the colocalization of D5 receptors with Galpha12 and Galpha13 in rat renal brush border membranes, immortalized rat renal proximal tubule cells, and D5 receptor-transfected HEK293 cells. In these cells, a D1-like agonist, fenoldopam, increased the association of Galpha12 and Galpha13 with D5 receptors, results that were corroborated by immunoprecipitation experiments. We conclude that although both D1 and D5 receptors are linked to Galphas, they are differentially linked to Galpha12 and Galpha13. The consequences of the differential G-protein subunit linkage on D1- and D5-mediated sodium transport remains to be determined.

Asunto(s)

Proteínas de Unión al ADN/metabolismo , Proteínas de Unión al GTP Heterotriméricas/metabolismo , Nefronas/metabolismo , Receptores de Dopamina D1/metabolismo , Animales , Línea Celular , Proteínas de Unión al ADN/análisis , Proteínas de Unión al ADN/inmunología , Subunidades alfa de la Proteína de Unión al GTP G12-G13 , Proteínas de Unión al GTP Heterotriméricas/análisis , Proteínas de Unión al GTP Heterotriméricas/inmunología , Humanos , Immunoblotting , Inmunohistoquímica , Riñón/química , Túbulos Renales Proximales/química , Túbulos Renales Proximales/metabolismo , Microscopía Confocal , Nefronas/química , Pruebas de Precipitina , Subunidades de Proteína , Ratas , Ratas Endogámicas WKY , Receptores de Dopamina D1/análisis , Receptores de Dopamina D1/inmunología , Receptores de Dopamina D5

RESUMEN

The role of adenosine deaminase in the interactions between adenosine A(1) and dopamine D(1) receptors was studied in a mouse fibroblast cell line stably cotransfected with human D(1) receptor and A(1) receptor cDNAs (A(1)D(1) cells). Confocal laser microscopy analysis showed a high degree of adenosine deaminase immunoreactivity on the membrane of the A(1)D(1) cells but not of the D(1) cells (only cotransfected with human D(1) receptor cDNAs). In double immunolabelling experiments in A(1)D(1) cells and cortical neurons a marked overlap in the distribution of the A(1) receptor and adenosine deaminase immunoreactivities and of the D(1) receptor and adenosine deaminase immunoreactivities was found. Quantitative analysis of A(1)D(1) cells showed that adenosine deaminase immunoreactivity to a large extent colocalizes with A(1) and D(1) receptor immunoreactivity, respectively. The A(1) receptor agonist caused in A(1)D(1) cells and in cortical neurons coaggregation of A(1) receptors and adenosine deaminase, and of D(1) receptors and adenosine deaminase. The A(1) receptor agonist-induced aggregation was blocked by R-deoxycoformycin, an irreversible adenosine deaminase inhibitor. The competitive binding experiments with the D(1) receptor antagonist [(3)H]SCH-23390 showed that the D(1) receptors had a better fit for two binding sites for dopamine, and treatment with the A(1) receptor agonist produced a disappearance of the high-affinity site for dopamine at the D(1) receptor. R-Deoxycoformycin treatment, which has previously been shown to block the interaction between adenosine deaminase and A(1) receptors, and which is crucial for the high-affinity state of the A(1) receptor, also blocked the A(1) receptor agonist-induced loss of high-affinity D(1) receptor binding. The conclusion of the present studies is that the high-affinity state of the A(1) receptor is essential for the A(1) receptor-mediated antagonistic modulation of D(1) receptors and for the A(1) receptor-induced coaggregates of A(1) and adenosine deaminase, and of D(1) and adenosine deaminase. Thus, the confocal experiments indicate that both A(1) and D(1) receptors form agonist-regulated clusters with adenosine deaminase, where the presence of a structurally intact adenosine deaminase bound to A(1) receptors is important for the A(1)-D(1) receptor-receptor interaction at the level of the D(1) receptor recognition.

Asunto(s)

Adenosina Desaminasa/metabolismo , Adenosina/análogos & derivados , Corteza Cerebral/metabolismo , Fibroblastos/metabolismo , Neuronas/metabolismo , Receptores de Dopamina D1/metabolismo , Receptores Purinérgicos P1/metabolismo , 2,3,4,5-Tetrahidro-7,8-dihidroxi-1-fenil-1H-3-benzazepina/farmacología , Adenosina/metabolismo , Adenosina/farmacología , Adenosina Desaminasa/inmunología , Animales , Línea Celular , Corteza Cerebral/citología , Humanos , Inmunohistoquímica , Ratones , Microscopía Confocal , Agonistas del Receptor Purinérgico P1 , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D1/inmunología , Receptores Purinérgicos P1/inmunología , Transfección